Drug Trial Radar · NCT00547898
Safety and Effectiveness of 3 Doses of Crofelemer Compared to Placebo in the Treatment of HIV Associated Diarrhea
Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
374
Actual
Start
Oct 2007
Primary completion
Jan 27, 2011
Study completion Jul 11, 2011
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center study. This study will compare an investigational new drug (crofelemer) to placebo for the control of HIV-associated diarrhea. The first stage of the study will determine the optimal dose of study drug based on safety and response to therapy and the second stage will evaluate further the effectiveness of the optimal dose.
Conditions
- HIV Associated Diarrhea
Interventions
Crofelemer 125 mgDrug
Crofelemer 125 mg
Crofelemer 250 mgDrug
Crofelemer 250 mg
Crofelemer 500 mgDrug
Crofelemer 500 mg
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose of Crofelemer Compared to PlaceboTime frame: 31 days
Locations
82 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Huntsville, Alabama
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Bakersfield, California
Site not named
Beverly Hills, California
Site not named
Beverly Hills, California
Site not named
Fountain Valley, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Oakland, California
Site not named
Palm Springs, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Mateo, California
Site not named
Denver, Colorado
Site not named
Daytona Beach, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Ft. Pierce, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
Orlando, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Wilton Manors, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Iowa City, Iowa
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Showing 40 of 82 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.